Facts and Fiction about Colistin from Clinical and Public Health Perspectives

Colistin Webinar

Facts and Fiction about Colistin from Clinical and Public Health Perspectives

Recorded on Tuesday, September 20, 2016

The resurrection of colistin as a last resort drug for treatment of multidrug resistant gram-negative bacilli (MDR GNB) has prompted clinicians and researchers to understand how this agent performs in the test tube and in the patient. Much has been learned but some aspects surrounding the use of colistin remain a mystery. This session will focus on colistin testing and reporting, colistin resistance due to mcr-1 and other resistance mechanisms and colistin dosing and administration. The goal is to bring laboratorians, clinicians, pharmacists and public health personnel up to date on the role of colistin in combatting infections due to MDR GNB in today’s healthcare settings.

Objectives:

  • List options for testing and reporting colistin for guiding treatment decisions and monitoring resistance
  • Discuss public health considerations for mcr-1-mediated resistance and other mechanisms of colistin resistance
  • Describe clinical parameters including pharmacokinetics/pharmacodynamics (PK/PD) for using colistin for the treatment of MDR GNB

Member Price: as low as $29.70

Nonmember Price: $99.00
Log in to see your price and add to cart

Publication Details

Date of Publication: September 20, 2016

Colistin Webinar Additional Details

Speakers:

Romney M. Humphries, PhD, D(ABMM) Section Chief, Clinical Microbiology UCLA David Geffen School of Medicine
Jean B. Patel, PhD, D(ABMM) Deputy Director, Office of Antimicrobial Resistance Centers for Disease Control and Prevention
David P. Nicolau, PharmD, FCCP, FIDSA Director Hartford Hospital